title: Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
authors.forename: L
authors.initials: L
authors.lastname: Rios-Buceta
authors.forename: G F
authors.initials: GF
authors.lastname: Buezo
authors.forename: P F
authors.initials: PF
authors.lastname: Peñas
authors.forename: E
authors.initials: E
authors.lastname: Dauden
authors.forename: J
authors.initials: J
authors.lastname: Fernandez-Herrera
authors.forename: A
authors.initials: A
authors.lastname: Garcia-Diez
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D007645:Keratoderma, Palmoplantar / Q000209:etiology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced*; D010292:Paresthesia / Q000139:chemically induced*; D013274:Stomach Neoplasms / Q000473:pathology; D005641:Tegafur / Q000009:adverse effects*; D014060:Tongue Diseases / Q000139:chemically induced*
chemical_list: D000964:Antimetabolites, Antineoplastic; D005641:Tegafur